Title:
AGENT FOR REVERSING RESISTANCE TO ANTICANCER DRUGS
Document Type and Number:
WIPO Patent Application WO/2021/251340
Kind Code:
A1
Abstract:
The present invention is achieved by characterizing a molecular mechanism involved in the inter-species difference in the efficacy of EGFR-TKI, and thereby focusing on the role of IL-26, which is present in humans but not in mice. The present inventors have found that human cancer is exposed to IL-26 in the tumor micro-environment (TME), so that the bypass path of EGFR-TKI is activated, while the suppression of IL-26 overcomes EGFR-TKI resistance in cancer. Furthermore, the present inventors have identified EphA3 as a novel functional receptor of TNBC for IL-26. Therefore, the present invention provides a pharmaceutical composition that is for treatment of cancer in a patient, and is used in conjunction with an anticancer drug, and that contains, as an active ingredient, a drug that reverses resistance to the anticancer drug caused by IL-26. The present invention also provides: a humanized anti-IL-26 antibody; and a therapeutic or prophylactic drug that is for refractory immune disorders or cancer and that uses the antibody.
More Like This:
Inventors:
MORIMOTO CHIKAO (JP)
OHNUMA KEI (JP)
HATANO RYO (JP)
ITOH TAKUMI (JP)
KANEKO YUTARO (JP)
OHNUMA KEI (JP)
HATANO RYO (JP)
ITOH TAKUMI (JP)
KANEKO YUTARO (JP)
Application Number:
PCT/JP2021/021576
Publication Date:
December 16, 2021
Filing Date:
June 07, 2021
Export Citation:
Assignee:
YS AC CO LTD (JP)
JUNTENDO EDUCATIONAL FOUND (JP)
JUNTENDO EDUCATIONAL FOUND (JP)
International Classes:
A61K45/06; A61K31/506; A61K31/517; A61K31/5377; A61K39/395; A61P15/00; A61P35/00; A61P37/02; A61P43/00; C07K16/30; C07K16/40; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/13; C12N15/63
Domestic Patent References:
| WO1999058572A1 | 1999-11-18 | |||
| WO2003054172A2 | 2003-07-03 | |||
| WO2004009823A1 | 2004-01-29 | |||
| WO2003064630A2 | 2003-08-07 |
Foreign References:
| JP2019099492A | 2019-06-24 | |||
| JP2019099492A | 2019-06-24 | |||
| US4816567A | 1989-03-28 | |||
| JP2009099492A | 2009-05-07 |
Other References:
YOU WEI, TANG QIYUN, ZHANG CHUANYONG, WU JINDAO, GU CHUNRONG, WU ZHENGSHAN, LI XIANGCHENG: "IL-26 Promotes the Proliferation and Survival of Human Gastric Cancer Cells by Regulating the Balance of STAT1 and STAT3 Activation", PLOS ONE, vol. 8, no. 5, pages e63588, XP093015496, DOI: 10.1371/journal.pone.0063588
XI, ZHI-FENG ET AL.: "Expression of IL -26 predicts prognosis of patients with hepatocellular carcinoma after surgical resection", HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, vol. 18, no. 3, 2019, pages 242 - 248, XP093015503
OFFENHÄUSER CAROLIN, AL-EJEH FARES, PUTTICK SIMON, ENSBEY KATHLEEN, BRUCE ZARA, JAMIESON PAUL, SMITH FIONA, STRINGER BRETT, CARRIN: "EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma", CANCERS, vol. 10, no. 12, 17 December 2018 (2018-12-17), pages 519, XP055885475, DOI: 10.3390/cancers10120519
CAIVANO ANTONELLA; LA ROCCA FRANCESCO; FAVOLE ALESSANDRA; CARTURAN SONIA; BRACCO ENRICO; VILLANI ORESTE; PIETRANTUONO GIUSEPPE; LA: "Identification of EpHA3 As a New Potential Molecular Target in Multiple Myeloma.", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 120, no. 21, 16 November 2012 (2012-11-16), US , pages 2926, XP086660758, ISSN: 0006-4971, DOI: 10.1182/blood.V120.21.2926.2926
ITOH TAKUMI, HATANO RYO, HORIMOTO YOSHIYA, YAMADA TAKETO, SONG DAN, OTSUKA HARUNA, SHIRAKAWA YUKI, MASTUOKA SHUJI, IWAO NORIAKI, A: "IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells", CELL DEATH & DISEASE, vol. 12, no. 6, XP093015506, DOI: 10.1038/s41419-021-03787-5
KNAPPE A ET AL., J VIROL, vol. 74, no. 8, 2000, pages 3881 - 3887
FICKENSCHER H ET AL., INT IMMUNOPHARMACOL, vol. 4, no. 5, 2004, pages 609 - 613
STEPHEN-VICTOR E ET AL., PLOS PATHOG, vol. 12, no. 6, 2016, pages 1005624
OHNUMA K ET AL., J IMMUNOL, vol. 194, no. 8, 2015, pages 3697 - 3712
ITOH T ET AL., J INVEST DERMATOL, vol. 139, no. 4, 2019, pages 878 - 889
COLLINS PL ET AL., J IMMUNOL, vol. 185, no. 3, 2010, pages 1492 - 1501
OHNUMA K ET AL., CRIT REV IMMUNOL, vol. 36, no. 3, 2016, pages 239 - 267
KAMIJO H ET AL., J INVEST DERMATOL, vol. 140, no. 3, 2020, pages 636 - 644
YOU W ET AL., PLOS ONE, vol. 8, no. 5, 2013, pages e63588
SUN H ET AL., FRONT IMMUNOL, vol. 10, no. 2819, 2019, pages 2819
DONNELLY RP ET AL., CYTOKINE GROWTH FACTOR REV, vol. 21, no. 5, 2010, pages 393 - 401
AOKI M ET AL., J BIOL CHEM, vol. 279, no. 31, 2004, pages 32643 - 32650
SHEIKH F ET AL., J IMMUNOL, vol. 172, no. 4, 2004, pages 2006 - 2010
JANES PW, ATLAS OF GENETICS AND CYTOGENETICS IN ONCOLOGY AND HAEMATOLOGY, no. 5, 2017
BOYD AW ET AL., NAT REV DRUG DISCOV, vol. 13, no. 1, 2014, pages 39 - 62
BOYD AW ET AL., J BIOL CHEM, vol. 267, no. 5, 1992, pages 3262 - 3267
CHIARI R ET AL., CANCER RES, vol. 60, no. 17, 2000, pages 4855 - 4863
LACKMANN M ET AL., PROC NATL ACAD SCI USA, vol. 93, no. 6, 1996, pages 2523 - 2527
JANES PW ET AL., GROWTH FACTORS, vol. 32, no. 6, 2014, pages 176 - 189
DAVIS S ET AL., SCIENCE, vol. 266, no. 5186, 1994, pages 816 - 819
LACKMANN M ET AL., J BIOL CHEM, vol. 273, no. 32, 1998, pages 20228 - 20237
CLIFFORD N ET AL., J CELL BIOCHEM, vol. 105, no. 5, 2008, pages 1250 - 1259
PASQUALE EB, NAT REV CANCER, vol. 10, no. 3, 2010, pages 165 - 180
NIEVERGALL E ET AL., J CELL BIOL, vol. 191, no. 6, 2010, pages 1189 - 1203
LISABETH EM ET AL., BIOCHEMISTRY, vol. 51, no. 7, 2012, pages 1464 - 1475
ZHUANG G ET AL., J NATL CANCER INST, vol. 104, no. 15, 2012, pages 1182 - 1197
DAY BW ET AL., CANCER CELL, vol. 23, no. 2, 2013, pages 238 - 248
QAZI MA ET AL., CANCER RES, vol. 78, no. 17, 2018, pages 5023 - 5037
VECCHI M ET AL., ONCOGENE, vol. 27, no. 15, 2008, pages 2148 - 2158
KOU CJ ET AL., BIOMED RES INT, vol. 2018, 2018, pages 7390104
GARRIDO-CASTRO AC ET AL., CANCER DISCOV, vol. 9, no. 2, 2019, pages 176 - 198
DENT R ET AL., CLIN CANCER RES, vol. 13, 2007, pages 4429 - 4434
FOULKES WD ET AL., N ENGL J MED, vol. 363, no. 20, 2010, pages 1938 - 1948
BIANCHINI G ET AL., NAT REV CLIN ONCOL, vol. 13, no. 11, 2016, pages 674 - 690
NAKHJAVANI M ET AL., J BREAST CANCER, vol. 22, no. 3, 2019, pages 341 - 361
CIARDIELLO F ET AL., N ENGL J MED, vol. 358, no. 11, 2008, pages 1160 - 1174
LIANG YJ ET AL., ONCOTARGET, vol. 8, no. 29, 2017, pages 47454 - 47473
MCLAUGHLIN RP ET AL., BREAST CANCER RES, vol. 21, no. 1, 2019, pages 77
NAKAI K ET AL., AM J CANCER RES, vol. 6, no. 8, 2016, pages 1609 - 1623
COSTA R ET AL., CANCER TREAT REV, vol. 53, 2017, pages 111 - 119
ALI R ET AL., SIGNAL TRANSDUCT TARGET THER, vol. 2, no. 1, 2017, pages 16042
LYNCH TJ ET AL., N ENGL J MED, vol. 350, no. 21, 2004, pages 2129 - 2139
GIOVANNINI M ET AL., J ONCOL, vol. 2009, 2009, pages 849051
LACOUTURE ME, NAT REV CANCER, vol. 6, no. 10, 2006, pages 803 - 812
ROZENCWEIG M ET AL., RECENT RESULTS CANCER RES, vol. 94, 1984, pages 1 - 7
KERN DH ET AL., CANCER RES, vol. 45, 1985, pages 5436 - 41
TANIGAWA N ET AL., EUR J CANCER, vol. 28, 1992, pages 31 - 4
FRUEHAUF JP ET AL., CANCER PRINCIPLE PRAC ONCOL, vol. 7, 1993, pages 12
CARMICHAEL J ET AL., CANCER RES, vol. 47, 1987, pages 936 - 42
WEISENTHAL LM ET AL., ONCOL HUNTINGT, vol. 5, 1991, pages 93 - 103
FRUEHAUF JP ET AL., CONTRIB GYNECOL OBSTET, vol. 19, 1994, pages 39 - 52
FURUKAWA T ET AL., CLIN CANCER RES, vol. 1, 1995, pages 305 - 11
YUUKI TAKAMURA ET AL., INT. J. CANCER, vol. 98, 2002, pages 450 - 455
"NCBI", Database accession no. NP_060872.1
NATURE BIOTECHNOLOGY, vol. 29, no. 1, 2011, pages 5 - 6
MANEESH JAIN ET AL., TRENDS IN BIOTECHNOLOGY, vol. 25, no. 7, 2007, pages 307 - 316
CHRISTOPH STEIN ET AL., ANTIBODIES, no. 1, 2012, pages 88 - 123
MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554
JEFFERISLUND, CHEM. IMMUNOL., vol. 65, 1997, pages 111 - 128
WRIGHTMORRISON, TIBTECH, vol. 15, 1997, pages 26 - 32
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO.
"Remington, The Science and Practice of Pharmacy", 2000, MACK PUBLISHING
HATANO R ET AL., MABS, 2019, pages 1 - 15
HATANO R ET AL.: "Histological and immunohistochemical methods were performed according", PLOS ONE, vol. 14, no. 6, 2019, pages e0218330
XUE T ET AL., J BUON, vol. 24, no. 1, 2019, pages 215 - 220
CROSBY EJ ET AL., ONCOIMMUNOLOGY, vol. 7, no. 5, 2018, pages e1421891
SAMENI M ET AL., CLIN CANCER RES, vol. 22, no. 4, 2016, pages 923 - 934
FUJII M ET AL., WORLD J GASTROENTEROL, vol. 23, no. 30, 2017, pages 5519 - 5529
WEE P ET AL., CANCERS (BASEL, vol. 9, no. 5, 2017
HAMMERMAN PS ET AL., CLIN CANCER RES, vol. 15, no. 24, 2009, pages 7502 - 7509
KAKUSHITA ET AL., METHODS, vol. 36, 2005, pages 69 - 83
DAHLKE, I., J. ALLERGY CLIN.IMMUNOL., vol. 117, 2006, pages 1477 - 1483
JARDINE, J. G. ET AL., SCIENCE, vol. 351, 2016, pages 1458 - 1463
XI, ZHI-FENG ET AL.: "Expression of IL -26 predicts prognosis of patients with hepatocellular carcinoma after surgical resection", HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, vol. 18, no. 3, 2019, pages 242 - 248, XP093015503
OFFENHÄUSER CAROLIN, AL-EJEH FARES, PUTTICK SIMON, ENSBEY KATHLEEN, BRUCE ZARA, JAMIESON PAUL, SMITH FIONA, STRINGER BRETT, CARRIN: "EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma", CANCERS, vol. 10, no. 12, 17 December 2018 (2018-12-17), pages 519, XP055885475, DOI: 10.3390/cancers10120519
CAIVANO ANTONELLA; LA ROCCA FRANCESCO; FAVOLE ALESSANDRA; CARTURAN SONIA; BRACCO ENRICO; VILLANI ORESTE; PIETRANTUONO GIUSEPPE; LA: "Identification of EpHA3 As a New Potential Molecular Target in Multiple Myeloma.", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 120, no. 21, 16 November 2012 (2012-11-16), US , pages 2926, XP086660758, ISSN: 0006-4971, DOI: 10.1182/blood.V120.21.2926.2926
ITOH TAKUMI, HATANO RYO, HORIMOTO YOSHIYA, YAMADA TAKETO, SONG DAN, OTSUKA HARUNA, SHIRAKAWA YUKI, MASTUOKA SHUJI, IWAO NORIAKI, A: "IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells", CELL DEATH & DISEASE, vol. 12, no. 6, XP093015506, DOI: 10.1038/s41419-021-03787-5
KNAPPE A ET AL., J VIROL, vol. 74, no. 8, 2000, pages 3881 - 3887
FICKENSCHER H ET AL., INT IMMUNOPHARMACOL, vol. 4, no. 5, 2004, pages 609 - 613
STEPHEN-VICTOR E ET AL., PLOS PATHOG, vol. 12, no. 6, 2016, pages 1005624
OHNUMA K ET AL., J IMMUNOL, vol. 194, no. 8, 2015, pages 3697 - 3712
ITOH T ET AL., J INVEST DERMATOL, vol. 139, no. 4, 2019, pages 878 - 889
COLLINS PL ET AL., J IMMUNOL, vol. 185, no. 3, 2010, pages 1492 - 1501
OHNUMA K ET AL., CRIT REV IMMUNOL, vol. 36, no. 3, 2016, pages 239 - 267
KAMIJO H ET AL., J INVEST DERMATOL, vol. 140, no. 3, 2020, pages 636 - 644
YOU W ET AL., PLOS ONE, vol. 8, no. 5, 2013, pages e63588
SUN H ET AL., FRONT IMMUNOL, vol. 10, no. 2819, 2019, pages 2819
DONNELLY RP ET AL., CYTOKINE GROWTH FACTOR REV, vol. 21, no. 5, 2010, pages 393 - 401
AOKI M ET AL., J BIOL CHEM, vol. 279, no. 31, 2004, pages 32643 - 32650
SHEIKH F ET AL., J IMMUNOL, vol. 172, no. 4, 2004, pages 2006 - 2010
JANES PW, ATLAS OF GENETICS AND CYTOGENETICS IN ONCOLOGY AND HAEMATOLOGY, no. 5, 2017
BOYD AW ET AL., NAT REV DRUG DISCOV, vol. 13, no. 1, 2014, pages 39 - 62
BOYD AW ET AL., J BIOL CHEM, vol. 267, no. 5, 1992, pages 3262 - 3267
CHIARI R ET AL., CANCER RES, vol. 60, no. 17, 2000, pages 4855 - 4863
LACKMANN M ET AL., PROC NATL ACAD SCI USA, vol. 93, no. 6, 1996, pages 2523 - 2527
JANES PW ET AL., GROWTH FACTORS, vol. 32, no. 6, 2014, pages 176 - 189
DAVIS S ET AL., SCIENCE, vol. 266, no. 5186, 1994, pages 816 - 819
LACKMANN M ET AL., J BIOL CHEM, vol. 273, no. 32, 1998, pages 20228 - 20237
CLIFFORD N ET AL., J CELL BIOCHEM, vol. 105, no. 5, 2008, pages 1250 - 1259
PASQUALE EB, NAT REV CANCER, vol. 10, no. 3, 2010, pages 165 - 180
NIEVERGALL E ET AL., J CELL BIOL, vol. 191, no. 6, 2010, pages 1189 - 1203
LISABETH EM ET AL., BIOCHEMISTRY, vol. 51, no. 7, 2012, pages 1464 - 1475
ZHUANG G ET AL., J NATL CANCER INST, vol. 104, no. 15, 2012, pages 1182 - 1197
DAY BW ET AL., CANCER CELL, vol. 23, no. 2, 2013, pages 238 - 248
QAZI MA ET AL., CANCER RES, vol. 78, no. 17, 2018, pages 5023 - 5037
VECCHI M ET AL., ONCOGENE, vol. 27, no. 15, 2008, pages 2148 - 2158
KOU CJ ET AL., BIOMED RES INT, vol. 2018, 2018, pages 7390104
GARRIDO-CASTRO AC ET AL., CANCER DISCOV, vol. 9, no. 2, 2019, pages 176 - 198
DENT R ET AL., CLIN CANCER RES, vol. 13, 2007, pages 4429 - 4434
FOULKES WD ET AL., N ENGL J MED, vol. 363, no. 20, 2010, pages 1938 - 1948
BIANCHINI G ET AL., NAT REV CLIN ONCOL, vol. 13, no. 11, 2016, pages 674 - 690
NAKHJAVANI M ET AL., J BREAST CANCER, vol. 22, no. 3, 2019, pages 341 - 361
CIARDIELLO F ET AL., N ENGL J MED, vol. 358, no. 11, 2008, pages 1160 - 1174
LIANG YJ ET AL., ONCOTARGET, vol. 8, no. 29, 2017, pages 47454 - 47473
MCLAUGHLIN RP ET AL., BREAST CANCER RES, vol. 21, no. 1, 2019, pages 77
NAKAI K ET AL., AM J CANCER RES, vol. 6, no. 8, 2016, pages 1609 - 1623
COSTA R ET AL., CANCER TREAT REV, vol. 53, 2017, pages 111 - 119
ALI R ET AL., SIGNAL TRANSDUCT TARGET THER, vol. 2, no. 1, 2017, pages 16042
LYNCH TJ ET AL., N ENGL J MED, vol. 350, no. 21, 2004, pages 2129 - 2139
GIOVANNINI M ET AL., J ONCOL, vol. 2009, 2009, pages 849051
LACOUTURE ME, NAT REV CANCER, vol. 6, no. 10, 2006, pages 803 - 812
ROZENCWEIG M ET AL., RECENT RESULTS CANCER RES, vol. 94, 1984, pages 1 - 7
KERN DH ET AL., CANCER RES, vol. 45, 1985, pages 5436 - 41
TANIGAWA N ET AL., EUR J CANCER, vol. 28, 1992, pages 31 - 4
FRUEHAUF JP ET AL., CANCER PRINCIPLE PRAC ONCOL, vol. 7, 1993, pages 12
CARMICHAEL J ET AL., CANCER RES, vol. 47, 1987, pages 936 - 42
WEISENTHAL LM ET AL., ONCOL HUNTINGT, vol. 5, 1991, pages 93 - 103
FRUEHAUF JP ET AL., CONTRIB GYNECOL OBSTET, vol. 19, 1994, pages 39 - 52
FURUKAWA T ET AL., CLIN CANCER RES, vol. 1, 1995, pages 305 - 11
YUUKI TAKAMURA ET AL., INT. J. CANCER, vol. 98, 2002, pages 450 - 455
"NCBI", Database accession no. NP_060872.1
NATURE BIOTECHNOLOGY, vol. 29, no. 1, 2011, pages 5 - 6
MANEESH JAIN ET AL., TRENDS IN BIOTECHNOLOGY, vol. 25, no. 7, 2007, pages 307 - 316
CHRISTOPH STEIN ET AL., ANTIBODIES, no. 1, 2012, pages 88 - 123
MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554
JEFFERISLUND, CHEM. IMMUNOL., vol. 65, 1997, pages 111 - 128
WRIGHTMORRISON, TIBTECH, vol. 15, 1997, pages 26 - 32
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO.
"Remington, The Science and Practice of Pharmacy", 2000, MACK PUBLISHING
HATANO R ET AL., MABS, 2019, pages 1 - 15
HATANO R ET AL.: "Histological and immunohistochemical methods were performed according", PLOS ONE, vol. 14, no. 6, 2019, pages e0218330
XUE T ET AL., J BUON, vol. 24, no. 1, 2019, pages 215 - 220
CROSBY EJ ET AL., ONCOIMMUNOLOGY, vol. 7, no. 5, 2018, pages e1421891
SAMENI M ET AL., CLIN CANCER RES, vol. 22, no. 4, 2016, pages 923 - 934
FUJII M ET AL., WORLD J GASTROENTEROL, vol. 23, no. 30, 2017, pages 5519 - 5529
WEE P ET AL., CANCERS (BASEL, vol. 9, no. 5, 2017
HAMMERMAN PS ET AL., CLIN CANCER RES, vol. 15, no. 24, 2009, pages 7502 - 7509
KAKUSHITA ET AL., METHODS, vol. 36, 2005, pages 69 - 83
DAHLKE, I., J. ALLERGY CLIN.IMMUNOL., vol. 117, 2006, pages 1477 - 1483
JARDINE, J. G. ET AL., SCIENCE, vol. 351, 2016, pages 1458 - 1463
Attorney, Agent or Firm:
NAGOYA INTERNATIONAL PATENT FIRM et al. (JP)
Download PDF: